Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Dipeptidyl peptidase-4 inhibitors may lower body temperature: A case-control study","authors":"Shuichi Okada ,&nbsp;Kazuya Okada ,&nbsp;Junichi Okada ,&nbsp;Koji Kikkawa ,&nbsp;Eijiro Yamada ,&nbsp;Tsugumichi Saito ,&nbsp;Tetsuro Andou ,&nbsp;Kihachi Ohshima ,&nbsp;Yawara Niijima","doi":"10.1016/j.dsx.2024.103142","DOIUrl":"10.1016/j.dsx.2024.103142","url":null,"abstract":"<div><h3>Aims</h3><div>Dipeptidyl peptidase-4 inhibitors (DPP4i) enhance GABAergic transmission via the glucagon-like peptide-1 (GLP-1)/GLP-1 receptor pathway. Oral γ-aminobutyric acid (GABA) administration reduces body temperature in humans; thus, DPP4i may reduce body temperature in humans. Therefore, this study aimed to determine the effects of DPP4i administration on the body temperature of patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>This study included 128 outpatients with T2D who visited the hospital monthly from May to July 2022. The DPP4i group included 64 patients treated with DPP4i while the non-DPP4i group included 64 patients not treated with DPP4i. Body temperature was measured at the axilla point upon entry to the hospital and was compared between the two groups.</div></div><div><h3>Results</h3><div>The means of age, body mass index, T2D duration, systolic blood pressure, diastolic blood pressure, serum creatinine level, casual triglyceride level, high-density lipoprotein cholesterol level, low-density lipoprotein cholesterol level, casual plasma glucose level, and glycated hemoglobin level were not significantly different between the two groups. The mean body temperatures (°C) were 36.1 ± 0.2 and 36.4 ± 0.17 in the DPP4i and non-DPP4i groups, respectively (<em>p</em> = 1.123 E−05).</div></div><div><h3>Conclusions</h3><div>DPP4i reduced the body temperature of patients with T2D.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103142"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum lipid peroxidation potential as a biomarker for risk-stratification of coronary artery disease in patients with type 2 diabetes mellitus","authors":"Kavya Sugur ,&nbsp;Swetha N. Kempegowda ,&nbsp;Sunil K. Shambu ,&nbsp;Manjappa Mahadevappa ,&nbsp;Vinay K. Kengegowda ,&nbsp;Jadeppa Gowda ,&nbsp;Rajesh K. Thimmulappa","doi":"10.1016/j.dsx.2024.103143","DOIUrl":"10.1016/j.dsx.2024.103143","url":null,"abstract":"<div><h3>Aim</h3><div>We examined the serum lipid peroxidation potential as an estimate of systemic oxidative stress levels in people with type 2 diabetes (T2D) for coronary artery disease (CAD) risk stratification.</div></div><div><h3>Methods</h3><div>We prospectively recruited patients and categorized them into four subgroups based on diabetes and severity of CAD [Gensini score &lt;20, non-significant CAD; Gensini score &gt;20, significant CAD]: non-diabetics with non-significant CAD, diabetics with non-significant CAD, non-diabetics with significant CAD and diabetics with significant CAD. Lipid profile, HbA1c, fasting blood glucose, and oxidized LDL were assessed. A newly developed assay estimated serum lipid peroxidation potential.</div></div><div><h3>Results</h3><div>Circulatory oxidized LDL levels were significantly higher in patients with severe CAD compared to non-diabetics with non-significant CAD, however no significant differences were observed across the four subgroups. Diabetics with non-significant CAD demonstrated significantly elevated serum lipid peroxidation potential compared to non-diabetics with non-significant CAD. Intriguingly, serum lipid peroxidation potential was markedly elevated in diabetics with non-significant CAD compared to both diabetics and non-diabetics with significant CAD. Poor glycemic control and reduced blood total antioxidant capacity were the primary factors contributing to increased serum lipid peroxidation potential in diabetics with non-significant CAD group.</div></div><div><h3>Conclusions</h3><div>We found that people with T2D who are associated with non-significant CAD are more vulnerable to oxidative stress than those with significant CAD. The study demonstrates the application of 'serum lipid peroxidation potential' assay for risk-stratification of CAD in people with T2D.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103143"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142555063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the Current Issue","authors":"Ningjian Wang ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103158","DOIUrl":"10.1016/j.dsx.2024.103158","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103158"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical effectiveness and safety of preoperative oral carbohydrate loading in patients with diabetes: A systematic review","authors":"Chunxiu Zhao ,&nbsp;Jinghong Shi ,&nbsp;Na Zhu ,&nbsp;Pingliang Yang ,&nbsp;Bingbing Xiang ,&nbsp;Yunke Dai ,&nbsp;Shun Wang","doi":"10.1016/j.dsx.2024.103140","DOIUrl":"10.1016/j.dsx.2024.103140","url":null,"abstract":"<div><h3>Background</h3><div>The effectiveness and safety of preoperative oral carbohydrate (POC) for people with diabetes remain controversial.</div></div><div><h3>Methods</h3><div>We systematically reviewed studies comparing POC to fasting or placebo in elective surgery for diabetic adults, focusing on gastric volume, postoperative complications, hospital stay, and glycemic control.</div></div><div><h3>Results</h3><div>Fourteen studies (n = 1870 patients) were included. POC did not significantly increase gastric volume or aspiration risk in well-controlled type 2 diabetes. Effects on perioperative glucose control varied. POC improved patient comfort and reduced preoperative hypoglycemia in gestational diabetes. Limited evidence suggested potential benefits in cardiac surgery patients.</div></div><div><h3>Conclusion</h3><div>POC is safe for well-controlled type 2 diabetics, enhancing comfort and reducing preoperative hypoglycemia without increasing aspiration risk. However, its effects on glucose control and postoperative outcomes vary. Personalized approaches are crucial, particularly for poorly controlled diabetes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 10","pages":"Article 103140"},"PeriodicalIF":4.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ٍEffects of Sumac Consumption on Blood Pressure, Glycemic Indices, and Body Composition in Adults: A GRADE-assessed Systematic Review and Dose-response Meta-analysis","authors":"Shaghayegh Taheri ,&nbsp;Zahra Sohrabi ,&nbsp;Hossein Bahari ,&nbsp;Seyedeh Nooshan Mirmohammadali ,&nbsp;Mohammad Hashem Hashempur ,&nbsp;Haniyeh Golafrouz ,&nbsp;Neda Haghighat ,&nbsp;Omid Asbaghi","doi":"10.1016/j.dsx.2024.103122","DOIUrl":"10.1016/j.dsx.2024.103122","url":null,"abstract":"<div><h3>Background</h3><div>Owing to the rich phytochemical content of <em>Rhus coriaria</em> L. (Anacardiaceae), known as Sumac, it may affect blood pressure, glycemic, and anthropometric indices. We, therefore, aimed to examine evidence on effect of Sumac on these factors by conducting a meta-analysis of RCTs.</div></div><div><h3>Methods</h3><div>A systematic literature search up to January 2024 was completed in PubMed/Medline, Scopus, and Web of Science. Heterogeneity tests of the selected trials were performed using the I² statistic. Random effects models were assessed based on the heterogeneity tests, and pooled data were determined as weighted mean differences (WMD) with a 95 % confidence interval (CI).</div></div><div><h3>Results</h3><div>Fifteen RCTs were included in this meta-analysis. Our findings showed that Sumac consumption significantly reduced diastolic blood pressure (DBP) (WMD = −2.88 mmHg; 95 %CI, −4.22 to −1.54; P = 0.001), fasting blood glucose (FBG) (WMD = −5.15 mg/dL; 95 %CI, −8.73 to −1.57; P = 0.005), insulin (WMD = −1.95 uIU/ml; 95 %CI, 3.11 to −0.79; P = 0.001), Hemoglobin A1c (WMD = −0.48 %; 95 %CI -0.84 to −0.12; P = 0.001), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (WMD = −0.71; 95 %CI, −1.14 to −0.27; P = 0.001), and waist to hip ratio (WHR) (WMD = −0.01; 95 %CI, −0.02 to −0.00; P = 0.017). Sumac consumption had no significant effects on weight, body mass index, and waist circumference.</div></div><div><h3>Conclusion</h3><div>We found that Sumac consumption could improve DBP, glycemic indices, and WHR. Also, supplementation of this herb in higher doses or longer durations had more promising effects on FBG, HOMA-IR, and WHR.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103122"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study","authors":"Mahmoud Nassar MD, PhD, MSc, MHA, MPA, CPHQ, SSBB ,&nbsp;Omar Nassar ,&nbsp;Hazem Abosheaishaa ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103116","DOIUrl":"10.1016/j.dsx.2024.103116","url":null,"abstract":"<div><h3>Background</h3><div>Acute pancreatitis (AP) is a significant health concern with potential for recurrent episodes and serious complications. The risk of recurrence in type 2 diabetes (T2D) or obesity can be influenced by various factors and treatments, including GLP-1 receptor agonists (GLP-1RAs). This study evaluates the risk of recurrent AP among patients with a history of the condition, focusing on the effects of different GLP-1RA treatments.</div></div><div><h3>Objectives</h3><div>Our objective is to compare the recurrence risks of AP between patients treated with different GLP-1RAs.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using the TriNetX platform, encompassing 258,238 individuals with T2D or obesity who have a history of AP. We assessed the recurrence of AP over a five-year period, analyzing data on treatment regimens, with a focus on the use of Semaglutide, Tirzepatide, and other GLP-1RAs.</div></div><div><h3>Results</h3><div>GLP-1RA users experienced significantly lower recurrence rates of AP, with those without risk factors showing GLP-1RA users had a recurrence rate of 13.8 % compared to 40.9 % for non-users. Semaglutide and Tirzepatide showed the most favorable outcomes; Semaglutide users had lower recurrence rates than Exenatide (10.1 % vs. 27 %) and slightly lower than Dulaglutide (13.6 % vs. 15.4 %), though not statistically significant with Dulaglutide. Tirzepatide users displayed the lowest recurrence risk at 6.2 %, significantly lower than those on Semaglutide (11.7 %).</div></div><div><h3>Conclusions</h3><div>GLP-1RAs, particularly Semaglutide and Tirzepatide, are associated with a reduced risk of recurrent AP in people with T2D or obesity. The differential risk profile between these drugs highlights the need for further studies and personalized treatment plans.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103116"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) ,&nbsp;Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2024.103141","DOIUrl":"10.1016/j.dsx.2024.103141","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103141"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific dietary patterns and their association with metabolic syndrome: Insights from a cross-sectional analysis","authors":"Mónica Lavinia Popescu ,&nbsp;María Rubín-García ,&nbsp;Laura Álvarez-Álvarez ,&nbsp;Estefanía Toledo ,&nbsp;Dolores Corella ,&nbsp;Jordi Salas-Salvadó ,&nbsp;Karla Alejandra Pérez-Vega ,&nbsp;J Alfredo Martínez ,&nbsp;Ángel M. Alonso-Gómez ,&nbsp;Julia Wärnberg ,&nbsp;Jesús Vioque ,&nbsp;Dora Romaguera ,&nbsp;José López-Miranda ,&nbsp;Ramón Estruch ,&nbsp;Francisco J. Tinahones ,&nbsp;José Lapetra ,&nbsp;Luís Serra-Majem ,&nbsp;Naomi Cano-Ibáñez ,&nbsp;Josep A. Tur ,&nbsp;Roi Naveiro ,&nbsp;Tania Fernández-Villa","doi":"10.1016/j.dsx.2024.103123","DOIUrl":"10.1016/j.dsx.2024.103123","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to identify <em>a posteriori</em> dietary patterns with a sex approach and to evaluate their association with metabolic syndrome criteria.</div></div><div><h3>Methods</h3><div>Cross-sectional study conducted in 6821 men and women between 55 and 75 years of age. Forty-two food groups were analyzed from dietary information collected with food frequency questionnaires, using principal component analysis and cluster analysis and then information from both statistical methods was compared. Prevalences were calculated foreach cluster group, based on the number and types of metabolic syndrome criteria they met.</div></div><div><h3>Results</h3><div>Following principal component analysis, two dietary patterns labeled “healthy” and “unhealthy” were identified in both men and women, due to the presence of foods that are considered more or less healthy. These same dietary patterns were found in cluster analysis plus an “intermediate” cluster consisting of both healthy and unhealthy foods. The presence of metabolic syndrome is related to the “healthy” dietary pattern in women and to the “unhealthy” dietary pattern in men. Comparison of the two statistical approaches showed a high level of correlation between them (weighted Kappa = 0.703 in women and weighted Kappa = 0.691 in men).</div></div><div><h3>Conclusions</h3><div>Adherence to both healthy and unhealthy dietary pattern appears to be related to the development of MS. The differences found by sex make it necessary to develop interventions with a sex-specific approach.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103123"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding obesity among young adults in India: A focus group study","authors":"Wareesha Anwar ,&nbsp;Piyush Ranjan ,&nbsp;Anita Malhotra ,&nbsp;Nikita Madan ,&nbsp;Archana Kumari ,&nbsp;Amandeep Singh ,&nbsp;Bindu Prakash ,&nbsp;Ranveer Singh Jadon ,&nbsp;Upendra Baitha ,&nbsp;Naval K. Vikram","doi":"10.1016/j.dsx.2024.103121","DOIUrl":"10.1016/j.dsx.2024.103121","url":null,"abstract":"<div><h3>Introduction</h3><div>The study aims to understand the knowledge and awareness about risk factors and consequences of obesity, barriers and motivators to weight loss, and potential solutions for weight management among young adults (YAs) in India.</div></div><div><h3>Method</h3><div>Six focus group discussions were conducted with an inductive approach among obese YAs (18–30 years) recruited through snowball and purposive sampling. The principle of maximum diversity was used to build a pool of varied and extensive information regarding obesity in YAs. The discussions were audio-recorded and transcribed verbatim using NVivo 1.0 by QSR International to generate codes, subthemes, and themes from the discussions.</div></div><div><h3>Result</h3><div>Among the thirty recruited YAs (mean age 24.7 ± 2.84 years), nearly half were from a high-income group (56.6 %) and had postgraduate education (53.3 %). Key themes included the need for increased awareness about obesity risk factors and consequences across different societal levels. Physical appearance was the primary motivator for weight loss, followed by physical endurance and social support. Major barriers included lack of energy, time, motivation, lifestyle changes, easy access to unhealthy foods, work commitments, and workplace culture. A holistic approach involving dietary changes, physical activity, and educational and policy reforms was suggested as potential solutions.</div></div><div><h3>Conclusion</h3><div>The challenges faced by YAs in developing countries regarding different aspects of the development and management of obesity are unique and different from the other population groups. Individualized weight management modules may be useful for managing obesity in this group.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103121"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of green coffee bean extract on blood pressure and heart rate: A systematic review and dose-response meta-analysis of randomized controlled trials","authors":"Simin Samavat ,&nbsp;Damoon Ashtary-Larky ,&nbsp;Fatemeh Naeini ,&nbsp;Behzad Nazarian ,&nbsp;Sara Kashkooli ,&nbsp;Cain C.T. Clark ,&nbsp;Reza Bagheri ,&nbsp;Omid Asbaghi ,&nbsp;Maryam Babaali ,&nbsp;Mohammad Ali Goudarzi ,&nbsp;Ali Zamanian ,&nbsp;Hadi Emamat","doi":"10.1016/j.dsx.2024.103120","DOIUrl":"10.1016/j.dsx.2024.103120","url":null,"abstract":"<div><h3>Background and aims</h3><div>The existing literature on the effects of green coffee bean extract (GCBE) consumption on systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) is equivocal. This study aimed to summarize the effects of GCBE consumption on SBP, DBP and HR in adults.</div></div><div><h3>Methods</h3><div>Data were pooled using a random-effects model and expressed as weighted mean difference (WMD) and 95 % confidence intervals (95 % CIs).</div></div><div><h3>Results</h3><div>Out of 1624 records, 10 studies that enrolled 563 participants were included. GCBE consumption significantly decreased SBP (WMD: −2.95 mmHg; 95 % CI: −4.27 to −1.62; p &lt; 0.001) and DBP (WMD: −2.15 mmHg; 95 % CI: −2.59 to −1.72; p &lt; 0.001). However, there was no significant effect on HR (WMD: −1.20 bpm; CI: −2.93 to 0.51; p = 0.170). Subgroup analysis showed that GCBE consumption had a more significant effect on SBP and DBP in participants with high SBP and DBP and had no effect on blood pressure in females. Linear and non-linear dose-response analyses were conducted to find the optimum GCBE dosage and duration of intervention. However, no significant associations were observed for SBP, DBP, and HR in linear meta-regression and non-linear dose-response based on the dose and duration of the intervention.</div></div><div><h3>Conclusion</h3><div>GCBE has the potential as a hypertension-reducing supplement in hypertensive patients. However, GCBE did not significantly change HR.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103120"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}